The Real Danger of Substandard and Counterfeit COVID-19 Vaccines

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume 2021 eBook
Issue 3
Pages: 10-14

Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.

AdobeStock_327257834_Leigh Prather - Counterfeit COVID-19 Vaccines

AdobeStock_327257834_Leigh Prather

As the COVID-19 pandemic continues, one pressing concern for the industry is ensuring the supply of legitimate COVID-19 vaccines. Now more than ever, the supply chain needs to be secure to ensure the population can have access to legitimate vaccines. But substandard and falsified COVID-19 vaccines—commonly referred to as counterfeit vaccines—continue to be a threat globally.

Regulatory Sourcebook

Read this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.

About the author

Meg Rivers is a senior editor at Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, September 2021
September 2021
Pages: 10-14

Citation

When referring to this article, please cite it as M. Rivers, “The Real Danger of Substandard and Counterfeit COVID-19 Vaccines," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).

Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology